Powering next-generation biologics through whole-genome strain optimisation
Phenotypeca’s platform is built around a single powerful concept: better strains mean better products and processes. At its core is our proprietary QTL strain optimisation technology, which enables us to deliver manufacturing strains capable of secreting difficult-to-express proteins at high yields, that are more stable at industrial scale, and better suited to the demands of modern biomanufacturing.
This technology underpins everything we do — from licensing ready-to-scale biosimilars to solving the toughest protein manufacturing problems and using evolutionary functional genomics to create breakthrough products.
Licensing patent-protected strains that are ready to scale
We use QTL technology to create products for licensing:
- Biosimilars — designed for quality, yield, and competitive pricing
- Therapeutics Biologics – high-value, low-risk therapeutics created using QTL technology
- Peptides – large & small peptides at affordable scale for the beauty industry
These strains are protected by a deep IP estate and are available to license for development and commercialisation.
Solving custom development challenges
The full value of biological products can be lost due to complications in manufacture and associated commercial restraints. We work with clients to realise the full value of their biosimilars, peptides and other protein products by creating optimised manufacturing strains for cost-efficient bioprocesses:
- Optimise upstream performance and meet cost and quality specifications
- Mitigate and reduce downstream processing losses and complexity
- Lower manufacturing costs and achieve market requirements
QTL Strain Optimisation: The Engine Behind It All
Phenotypeca’s QTL (Quantitative Trait Locus) optimisation technology is a patented method that uses vast genetic diversity and evolution to unlock the power of the entire genome to provide production strains optimised to the specific technical and commercial requirements of each biologic product.
Unlike traditional engineering or mutagenesis, QTL technology optimises multiple valuable traits simultaneously through a large-scale breeding programme. Areas of application include:
- Creation of low cost, consistently high quality biosimilars equivalent to recognised reference standards
- Scalable manufacture of large peptides at commercial cost for skincare
- Using evolutionary functional genomics to create and discover new biological products
Validated. Scalable. IP-Protected.
- Designed for manufacturing at industrial scale
- Protected by a robust IP portfolio
- Proven in multiple projects including one supported by the Bill and Melinda Gates Foundation
